Galderma Achieves Record 2 B USD Net Sales for a SixMonth Period in H1 2023 as It Continues to Demonstrate Leading Execution and Innovation Capabilities in Dermatology
In the first half of 2023 Galderma reached the 2 B USD net sales mark for the period for the first time and delivered the majority of Core EBITDA margin expansion planned by year end with Core EBITDA of 450 M USD and a 22.5 margin representing a 10.5 constant currency growth compared to the first half of 2022 and a margin increase of 150 bps versus the full year 2022.
Source: businesswireindia.com